Ultime notizie per Zynex (NASDAQ:ZYXI) Azioni

ZYNEX INC

Zynex

Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.

Zynex Inc

Throughout the last three months, 4 analysts have evaluated Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $8.12, a high estimate of $15.00, and a low estimate of $4.00. Highlighting a 32.33% decrease, the current average has fallen from the previous average price target of $12.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1746043262_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Zynex is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$4.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$5.50</td>
<td>$11.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Zynex. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Zynex compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Zynex's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ZYXI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Zynex analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Zynex: A Closer Look</h2>
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.
<h3>Breaking Down Zynex's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Zynex's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -2.77%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Zynex's net margin excels beyond industry benchmarks, reaching -1.34%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -1.72%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Zynex's ROA stands out, surpassing industry averages. With an impressive ROA of -0.5%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Zynex's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.07, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

ZYXI

4 Analysts Assess Zynex: What You Need To Know

RBC Capital analyst Shagun Singh maintains Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) with a Sector Perform and lowers the price target from $5 to $4.

News

Price Target

RBC Capital Maintains Sector Perform on Zynex, Lowers Price Target to $4

<h3>Gainers</h3>
<ul>
<li>Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) shares increased by 132.5% to $7.83 during Wednesday's regular session. The company's market cap stands at $519.0 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock increased by 71.13% to $54.08. The company's market cap stands at $703.7 million. </li>
<li>INVO Fertility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVF#NASDAQ">IVF</a>) shares increased by 62.72% to $2.62. The company's market cap stands at $12.9 million. As per the press release, Q4 earnings came out 2 days ago. </li>
<li>Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) shares moved upwards by 30.18% to $6.9. The market value of their outstanding shares is at $334.8 million. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) stock increased by 24.26% to $7.06. The company's market cap stands at $78.3 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) stock rose 20.73% to $1.31. The market value of their outstanding shares is at $7.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>GeneDx Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) stock declined by 38.7% to $71.69 during Wednesday's regular session. The company's market cap stands at $2.0 billion. As per the news, the Q1 earnings report came out today. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) stock decreased by 23.59% to $2.83. The company's market cap stands at $2.3 million. </li>
<li>Coeptis Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) stock declined by 21.78% to $7.76. The market value of their outstanding shares is at $25.1 million. </li>
<li>Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) stock fell 21.53% to $1.75. The market value of their outstanding shares is at $52.8 million. The company's, Q1 earnings came out yesterday. </li>
<li>Immunic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>) shares decreased by 15.63% to $1.08. The company's market cap stands at $103.4 million. </li>
<li>Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) shares fell 15.54% to $0.25. The market value of their outstanding shares is at $11.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ABEO

BCLI

CLRB

COEP

IMUX

NAOV

NTRB

RGLS

12 Health Care Stocks Moving In Wednesday's Intraday Session

WIIM

Zynex shares are trading lower after the company reported worse-than-expected Q1 financial results.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler raised Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) price target from $383 to $384. Piper Sandler analyst Arvind Ramnani maintained an Overweight rating. Visa shares closed at $341.52 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/V/analyst-ratings">view this stock</a>.</li>
<li>TD Securities cut the price target for Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) from $102 to $90. TD Securities analyst Agnes Lim maintained a Buy rating. Starbucks shares closed at $84.85 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/SBUX/analyst-ratings">view this stock</a>.</li>
<li>Needham cut AtriCure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) price target from $51 to $44. Needham analyst Mike Matson maintained a Buy rating. AtriCure shares closed at $34.65 on Tuesday. See how other <a href="https://www.benzinga.com/quote/ATRC/analyst-ratings">analysts view this stock</a>.</li>
<li>DA Davidson cut the price target for Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) from $170 to $155. DA Davidson analyst Tom White upgraded the stock from Neutral to Buy. Airbnb shares closed at $125.49 on Tuesday. <a href="https://www.benzinga.com/quote/ABNB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan cut the price target for PACCAR Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) from $105 to $90. JP Morgan analyst Tami Zakaria downgraded the stock from Overweight to Neutral. PACCAR shares closed at $90.29 on Tuesday. <a href="https://www.benzinga.com/quote/PCAR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Leerink Partners lowered NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) price target from $25 to $9. Leerink Partners analyst Puneet Souda downgraded the stock from Outperform to Market Perform. NeoGenomics shares settled at $6.58 on Tuesday. <a href="https://www.benzinga.com/quote/NEO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners cut Quanterix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTRX#NASDAQ">QTRX</a>) price target from $12 to $8. Leerink Partners analyst Puneet Souda downgraded the stock from Outperform to Market Perform. Quanterix shares closed at $6.05 on Tuesday. <a href="https://www.benzinga.com/quote/QTRX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. cut Zynex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) price target from $15 to $8. HC Wainwright &amp; Co. analyst Yi Chen maintained a Buy rating. Zynex shares closed at $2.23 on Tuesday.  <a href="https://www.benzinga.com/quote/ZYXI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup lowered the price target for Warby Parker Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRBY#NYSE">WRBY</a>) from $23 to $19. Citigroup analyst Paul Lejuez upgraded the stock from Sell to Neutral. Warby Parker shares settled at $15.80 on Tuesday. <a href="https://www.benzinga.com/quote/WRBY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank increased T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) price target from $275 to $277.5. Scotiabank analyst Maher Yaghi upgraded the stock from Sector Perform to Sector Outperform. T-Mobile US shares closed at $241.59 on Tuesday. <a href="https://www.benzinga.com/quote/TMUS/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying Visa stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30073519/image-231-1024x593.png" alt="" class="wp-image-894667" style="width:532px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30073519/image-231-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30073519/image-231-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30073519/image-231-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30073519/image-231.png 1106w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45064976/top-3-industrials-stocks-which-could-rescue-your-portfolio-in-q2">Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

ABNB

ATRC

PCAR

QTRX

SBUX

TMUS

WRBY

Visa To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday

HC Wainwright &amp; Co. analyst Yi Chen maintains Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) with a Buy and lowers the price target from $15 to $8.

HC Wainwright & Co. Maintains Buy on Zynex, Lowers Price Target to $8

Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) Q2 expected to be more than $(0.20) vs $(0.12) Est. Q2 Revenue expected to be more than $27.00M vs $33.75M Est

Guidance

Zynex Q2  expected to be more than $(0.20) vs $(0.12) Est; Q2  Revenue expected to be more than $27.00M vs $33.75M Est

Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.24) by 37.5 percent. The company reported quarterly sales of $26.58 million which missed the analyst consensus estimate of $30.83 million by 13.79 percent. This is a 42.88 percent decrease over sales of $46.53 million the same period last year.

Earnings

Earnings Misses

Zynex Q1 EPS $(0.33) Misses $(0.24) Estimate, Sales $26.58M Miss $30.83M Estimate

ACGL

AEYE

AMSF

APAM

ARCB

ARCC

ASTE

ASTL

BBIO

BBVA

BGFV

BKNG

BRSP

CECO

CHCT

CLVT

CSGP

CVLT

DHIL

ENSG

ENVA

ESRT

ETWO

EXLS

FELE

FFIC

FIBK

FICO

FOUR

FRSH

FRST

FSLR

FYBR

HLMN

HOUS

HRZN

HSBC

HURN

ILPT

INCY

INTZ

JAKK

JBGS

JBLU

KNSA

LFUS

LGIH

Laboratory Corporation Of America Holdings

LOGI

LXFR

Earnings Scheduled For April 29, 2025

Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Zynex to report an earnings per share (EPS) of $-0.24.
The announcement from Zynex is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Past Earnings Performance</h3>
The company's EPS missed by $0.11 in the last quarter, leading to a 51.29% drop in the share price on the following day.
Here's a look at Zynex's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.09</td>
<td>0.06</td>
<td>0.08</td>
<td>0.03</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.02</td>
<td>0.07</td>
<td>0.04</td>
<td>0</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-51.0%</td>
<td>6.0%</td>
<td>-12.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745874149_0.png" alt="eps graph" />
<h3>Zynex Share Price Analysis</h3>
Shares of Zynex were trading at $2.41 as of April 25. Over the last 52-week period, shares are down 79.54%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Analyst Opinions on Zynex</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Zynex.
Zynex has received a total of 2 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $10.25, the consensus suggests a potential 325.31% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of Fractyl Health, Hyperfine and CytoSorbents, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Fractyl Health, with an average 1-year price target of $11.0, suggesting a potential 356.43% upside.</li>
<li>Analysts currently favor an Buy trajectory for Hyperfine, with an average 1-year price target of $1.33, suggesting a potential 44.81% downside.</li>
<li>Analysts currently favor an Buy trajectory for CytoSorbents, with an average 1-year price target of $7.0, suggesting a potential 190.46% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
The peer analysis summary outlines pivotal metrics for Fractyl Health, Hyperfine and CytoSorbents, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zynex</td>
<td>Buy</td>
<td>-2.77%</td>
<td>$35.99M</td>
<td>-1.72%</td>
</tr>
<tr>
<td>Fractyl Health</td>
<td>Buy</td>
<td>-57.14%</td>
<td>$3K</td>
<td>-63.42%</td>
</tr>
<tr>
<td>Hyperfine</td>
<td>Buy</td>
<td>-13.59%</td>
<td>$826K</td>
<td>-19.36%</td>
</tr>
<tr>
<td>CytoSorbents</td>
<td>Buy</td>
<td>24.52%</td>
<td>$9.40M</td>
<td>-65.41%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Zynex ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity. Overall, Zynex is performing well in terms of revenue and profit compared to its peers, but its return on equity is lower in comparison.
<h3>About Zynex</h3>
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.
<h3>Financial Milestones: Zynex's Journey</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Zynex's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -2.77%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Zynex's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.34% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Zynex's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.72% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Zynex's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.5% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.07, caution is advised due to increased financial risk.
<a href="https://www.benzinga.com/quote/ZYXI/earnings">To track all earnings releases for Zynex visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Zynex

<h3>Gainers</h3>
<ul>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares increased by 49.2% to $12.61 during Monday's pre-market session. The market value of their outstanding shares is at $20.7 million. </li>
<li>CG Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) stock rose 43.49% to $32.1. The company's market cap stands at $2.4 billion. </li>
<li>Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) stock rose 30.93% to $5.63. The market value of their outstanding shares is at $15.3 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) shares moved upwards by 23.34% to $1.48. The market value of their outstanding shares is at $2.8 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares increased by 16.78% to $2.43. The market value of their outstanding shares is at $5.9 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) shares moved upwards by 12.54% to $3.32. The company's market cap stands at $4.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) shares fell 32.7% to $0.09 during Monday's pre-market session. The market value of their outstanding shares is at $3.6 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock declined by 22.09% to $1.27. The company's market cap stands at $1.8 million. </li>
<li>Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) shares declined by 14.94% to $2.05. The market value of their outstanding shares is at $61.9 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) stock decreased by 12.66% to $0.64. The company's market cap stands at $1.3 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) shares declined by 12.62% to $0.28. The company's market cap stands at $14.5 million. </li>
<li>Upstream Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPB#NASDAQ">UPB</a>) shares declined by 9.3% to $7.61. The company's market cap stands at $408.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

BNGO

CGON

PRTG

SLRX

SPRB

SXTP

THAR

12 Health Care Stocks Moving In Monday's Pre-Market Session

Revealing a significant insider sell on March 18, Thomas Sandgaard, President at Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>), as per the latest SEC filing.
What Happened: Sandgaard's recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000846475/000110465925024556//Archives/edgar/data/846475/000110465925024556/0001104659-25-024556-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday unveiled the sale of 1,700,000 shares of Zynex. The total transaction value is $4,938,500.
In the Tuesday's morning session, Zynex's shares are currently trading at $2.9, experiencing a down of 0.0%.
<h3>Delving into Zynex's Background</h3>
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.
<h3>Zynex's Financial Performance</h3>
Revenue Challenges: Zynex's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -2.77%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 78.29%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Zynex exhibits below-average bottom-line performance with a current EPS of -0.02.
</li>
</ul>
Debt Management: Zynex's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.07, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 32.22, Zynex's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 0.49 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio of 11.74, the company's market valuation exceeds industry averages.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000846475">Check Out The Full List Of Zynex's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Thomas Sandgaard Takes Money Off The Table, Sells $4.94M In Zynex Stock

<h3>Gainers</h3>
<ul>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) stock increased by 151.1% to $5.93 during Wednesday's regular session. The market value of their outstanding shares is at $48.9 million. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) shares rose 35.74% to $5.62. The company's market cap stands at $103.5 million. As per the press release, Q4 earnings came out today. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares increased by 26.86% to $0.41. The market value of their outstanding shares is at $2.6 million. </li>
<li>HeartSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) stock increased by 19.86% to $3.5. The market value of their outstanding shares is at $3.4 million. </li>
<li>Baird Medical Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) stock rose 18.18% to $5.46. The market value of their outstanding shares is at $198.5 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) shares moved upwards by 18.18% to $0.5. The market value of their outstanding shares is at $2.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) stock fell 53.9% to $3.23 during Wednesday's regular session. The market value of their outstanding shares is at $102.8 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) shares decreased by 40.6% to $0.05. </li>
<li>Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) stock decreased by 30.23% to $0.09. The company's market cap stands at $2.5 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock declined by 29.42% to $0.6. The company's market cap stands at $6.9 million. </li>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) shares fell 25.24% to $1.13. The market value of their outstanding shares is at $3.5 million. </li>
<li>Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) shares declined by 18.54% to $0.09. The market value of their outstanding shares is at $1.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDMD

CRVO

CUTR

HCTI

HEPA

HSCS

OPRX

SHPH

SYRS

TNON

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Jefferies analyst Kaumil Gajrawala downgraded the rating for PepsiCo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) from Buy to Hold and lowered the price target from $171 to $170. PepsiCo shares closed at $152.33 on Tuesday. <a href="https://www.benzinga.com/quote/pep/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Ladenburg Thalmann analyst Jeffrey Cohen downgraded Zynex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) from Buy to Neutral. Zynex shares closed at $7.00 on Tuesday. <a href="https://www.benzinga.com/quote/zyxi/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush analyst Robert Driscoll downgraded Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) from Outperform to Neutral and lowered the price target from $57 to $12. Arvinas shares closed at $8.30 on Tuesday. <a href="https://www.benzinga.com/quote/arvn/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Graham Doyle downgraded the rating for Smith &amp; Nephew plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNN#NYSE">SNN</a>) from Buy to Neutral. Smith &amp; Nephew shares closed at $29.84 on Tuesday. <a href="https://www.benzinga.com/quote/snn/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Maggie Nolan downgraded Magic Software Enterprises Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGIC#NASDAQ">MGIC</a>) from Outperform to Market Perform. Magic Software shares closed at $13.39 on Tuesday. <a href="https://www.benzinga.com/quote/mgic/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PEP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="602" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12130446/image-88-1024x602.png" alt="" class="wp-image-821432" style="width:642px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12130446/image-88-1024x602.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12130446/image-88-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12130446/image-88-768x451.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12130446/image-88.png 1152w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44274110/top-2-industrials-stocks-that-may-collapse-in-march">Top 2 Industrials Stocks That May Collapse In March</a></li>
</ul>

Downgrades

ARVN

MGIC

This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

RBC Capital analyst Shagun Singh downgrades Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) from Outperform to Sector Perform and lowers the price target from $11 to $5.5.

RBC Capital Downgrades Zynex to Sector Perform, Lowers Price Target to $5.5

Ladenburg Thalmann analyst Jeffrey Cohen downgrades Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) from Buy to Neutral.

Ladenburg Thalmann Downgrades Zynex to Neutral

Zynex shares are trading lower after HC Wainwright & Co. cut its price target on the stock from $17 to $15.

HC Wainwright &amp; Co. analyst Yi Chen maintains Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) with a Buy and lowers the price target from $17 to $15.

HC Wainwright & Co. Maintains Buy on Zynex, Lowers Price Target to $15

Zynex shares are trading lower following worse-than-expected Q4 financial results.

First Quarter 2025 Guidance
The Company expects Q1 2025 net revenue of at least $30 million. Loss per share is expected to be ($0.30) per share or better. The Company expects quarterly revenues to increase throughout the year with the usual seasonality typically experienced. The reduction in expenses which were undertaken throughout the second half of 2024 and more aggressively during Q1 2025 will show a significant impact on the bottom line in Q2 and going forward.

Zynex Sees Q1 2025 EPS $(0.30) Or Better; Revenue Of Atleast $30M

Legal

Press Releases

DEADLINE ALERT for TBBK, ZYXI, PPTA, and UCTT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 19, 2025 in Zynex, Inc. Lawsuit – ZYXI

Zynex (ZYXI) Hit by TriCare Suspension on Multiple Fronts: Weak Earnings and Investor Lawsuit – Hagens Berman

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bancorp, Zynex, enCore, and TFI and Encourages Investors to Contact the Firm

Zynex, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before May 19, 2025 to Discuss Your Rights - ZYXI

Zynex, Inc. (ZYXI) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Zynex, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before May 19, 2025 to Discuss Your Rights – ZYXI

Class Action Filed Against Zynex, Inc. (ZYXI) - May 19, 2025 Deadline to Join - Contact Levi & Korsinsky

Deadline Alert: Zynex, Inc. (ZYXI) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

ZYXI Deadline: ZYXI Investors with Losses in Excess of $100K Have Opportunity to Lead Zynex, Inc. Securities Fraud Lawsuit

PPTA

TBBK

TFII

UCTT

Apyx Medical

HeartBeam

BioSig Technologies

Envoy Medical, Inc. - Class A Common Stock

Envoy Medical

CytoSorbents

Daxor

electroCore

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

Zynex

Notizie

Ultime notizie per Zynex (NASDAQ:ZYXI) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO